174 related articles for article (PubMed ID: 38534947)
1. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).
Quartuccio N; Ialuna S; Scalisi D; D'Amato F; Barcellona MR; Bavetta MG; Fusco G; Bronte E; Musso E; Bronte F; Picciotto V; Carroccio A; Verderame F; Malizia G; Cistaro A; La Gattuta F; Moreci AM
Curr Oncol; 2024 Mar; 31(3):1504-1514. PubMed ID: 38534947
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
3. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
4. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
6. Radioembolization for the treatment of hepatocellular carcinoma.
Kim HC
Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
8. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
10.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
11. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.
Zori AG; Ismael MN; Limaye AR; Firpi R; Morelli G; Soldevila-Pico C; Suman A; Vogel JD; Lazarowicz M; Geller BS; Toskich B; Gonzalo DH; Johnson MW; Cabrera R
Am J Clin Oncol; 2020 May; 43(5):325-333. PubMed ID: 32079854
[TBL] [Abstract][Full Text] [Related]
12. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
13. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Y90 Radioembolization for Hepatocellular Carcinoma in Patients Previously Treated with Transarterial Embolization.
Zhao K; Son S; Karimi A; Marinelli B; Erinjeri JP; Alexander ES; Sotirchos VS; Harding JJ; Soares KC; Ziv E; Covey A; Sofocleous CT; Yarmohammadi H
Curr Oncol; 2024 May; 31(5):2650-2661. PubMed ID: 38785481
[TBL] [Abstract][Full Text] [Related]
15. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma.
Labgaa I; Tabrizian P; Titano J; Kim E; Thung SN; Florman S; Schwartz M; Melloul E
HPB (Oxford); 2019 Nov; 21(11):1497-1504. PubMed ID: 31005494
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.
Villalobos A; Arndt L; Cheng B; Dabbous H; Loya M; Majdalany B; Bercu Z; Kokabi N
J Vasc Interv Radiol; 2023 Jul; 34(7):1226-1234. PubMed ID: 36958669
[TBL] [Abstract][Full Text] [Related]
19. Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment.
Thayer D; Noda C; Charalel R; Mills A; Chang R; Tao Y; Akinwande O
J Comp Eff Res; 2018 Apr; 7(4):343-356. PubMed ID: 29553286
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]